Tilray Brands에 대한 매도 수량은 투자자에게 Tilray Brands의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Tilray Brands (NASDAQ:TLRY) 주식, 공매도 수량 보고

Tilray Brands

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

Cannabis

Earnings

News

Movers

TLRY

틸레이 브랜즈(NASDAQ:TLRY)는 월요일 시장 마감 후 2024 회계연도 4분기 재무 결과를 발표했다. 이번 분기의 주요 지표를 살펴보세요.

틸레이: 4분기 매출 및 EPS 예상 상회에 주가 급등, 대마초, 음료 및 웰빙의 융합을 선도

Tilray Brands Inc

TILRAY BRANDS ORD

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CWWBF">Plant Based Investment</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWWBF#OTC">CWWBF</a>) shares closed up 9900.00% at $0.0001</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 38.10% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 12.40% at $2.38</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 10.71% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 9.30% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 8.73% at $13.20</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 7.11% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 3.84% at $0.01</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/AUSAF">Australis Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 16.41% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 10.40% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 8.30% at $4.41</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed down 7.96% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 6.68% at $19.23</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 5.80% at $1.33</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 4.28% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.98% at $1.68</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 3.76% at $2.05</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 3.70% at $2.57</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 3.57% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 3.39% at $1.99</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Markets

AUSAF

BBRRF

CBDY

CLSH

CNPOF

CRBP

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CANNIBIS GROWTH OPTY CORP by Cannabis Growth Opportunity Corp.

CWWBF

CXXIF

ELLXF

FFNTF

GRWG

SNDL

TGIFF

UGRO

XXII

YCBD

Cannabis Stock Gainers And Losers From October 1, 2024

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) will release its financial results on Oct. 10, 2024 before financial markets open and host a live conference call to discuss the results at 8:30 am ET the same day.
In July, Tilray reported fiscal fourth-quarter revenue of $229.882 million, up approximately 25% year-over-year. Cannabis net revenue increased&nbsp;12%&nbsp;to&nbsp;$71.9 million in the quarter, while beverage-alcohol net revenue jumped&nbsp;137%&nbsp;to&nbsp;$76.7 million for the period.
Irwin Simon, chairman and CEO of Tilray Brands <a href="https://www.benzinga.com/markets/cannabis/24/07/40023244/tilray-q4-earnings-revenue-eps-beat-as-cannabis-beverages-wellness-converge-on-a-global-scale-dr">said at the time</a> that the company is "leading the convergence of cannabis, beverages, and wellness on a global scale."
Simon has spoken at previous Benzinga cannabis events sharing valuable tips for businesses within the burgeoning industry. The upcoming two-day event, the 19th Benzinga Cannabis Capital Conference, returns to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/01101339/ccc-oct-24-banner__1_-2.gif" alt="" class="wp-image-574784" /></a></figure>
<a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic</a>, senior analyst at Zuanic &amp; Associates <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40036301/tilray-should-be-a-long-term-holding-in-any-global-portfolio-of-cannabis-stocks-say">wrote in his post-earnings</a> analyst note that "TLRY should be a long-term holding in any global portfolio of cannabis stocks,&#8221; adding the company&#8217;s liquidity, large market cap and notable cash balance, plus assets, make it a &#8220;more credible&#8221; long-term investment.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/40076821/tilray-ceo-on-future-of-cannabis-and-federal-rescheduling-we-did-not-sit-back-and-wait">Tilray CEO On Future Of Cannabis And Federal Rescheduling: &#8216;We Did Not Sit Back And Wait&#8217;</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Recent Moves</h3>
In early September, Tilray <a href="https://www.benzinga.com/markets/cannabis/24/09/40690381/billion-dollar-cannabis-company-closes-acquisition-of-three-us-breweries-whats-next-for-tilray">closed on acquisitions</a> of four U.S. breweries from from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>). The acquisitions of Hop Valley Brewing Company,Terrapin Beer Co., Revolver Brewing and <a href="https://www.benzinga.com/markets/cannabis/24/09/40852419/billion-dollar-marijuana-giant-buys-another-brewery-from-molson-coors-expands-great-lakes-footpr">Atwater Brewery</a>, bolstered the company's leadership position in the U.S. craft beer market as the 5th largest craft brewer in the country and top craft brewer in the Pacific Northwest and Georgia.
Meanwhile, Tilray did not neglect the cannabis side of its business.
In August, the company <a href="https://www.benzinga.com/markets/cannabis/24/08/40510926/tilray-is-not-giving-up-on-cannabis-ramps-up-its-canadian-portfolio-on-heels-of-buying-four-us-b">announced the release</a> of its latest small-batch flower strain, Milk &amp; Cookies, under its premium cannabis brand Broken Coast.
In addition to the launch of Redecan EU-GMP-certified medical <a href="https://www.benzinga.com/topic/australia">marijuana products in Australia,</a> Tilray also introduced a new line of hemp-derived Delta-9 THC <a href="https://www.benzinga.com/markets/cannabis/24/09/41009554/tilray-brands-launches-hemp-derived-delta-9-thc-drinks-in-key-u-s-markets">beverages across key U.S. markets in September</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40901036/tilray-acquires-23-8m-promissory-note-in-deal-with-double-diamond-on-heels-of-brewery-acquisitio">&nbsp;Tilray Acquires $23.8M Promissory Note In Deal With Double Diamond On Heels Of Brewery Acquisition</a></li>
</ul>
<h3 class="wp-block-heading">TLRY Price Action</h3>
Tilray's shares traded 0.8523% lower at $1.745 per share at the time of writing on Tuesday morning.

Billion-Dollar Cannabis Giant Tilray To Report Earnings, Here's What Investors Can Expect

Legal

AKAN

CRON

IMCC

LFLY

MAPS

MSOS

Lawmakers Urge DEA To Finalize Marijuana Rescheduling Proposal

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) stock is trading higher on Monday, along with other shares in the cannabis sector, following a report suggesting that Vice President Kamala Harris wants to <a href="https://www.benzinga.com/markets/cannabis/24/09/41009554/tilray-brands-launches-hemp-derived-delta-9-thc-drinks-in-key-u-s-markets">legalize marijuana</a>.
What To Know: Harris said in an <a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/">interview</a> on the All the Smoke podcast that, &#8220;I just think we have come to a point where we have to understand that we need to legalize it and stop criminalizing this behavior.&#8221;
Harris also stated that, &#8220;I just feel strongly, people should not be going to jail for smoking weed. And we know historically what that has meant and who has gone to jail."
The episode of the podcast was released Monday. Its hosts are former NBA players Matt Barnes and Stephen Jackson. Other stocks in the cannabis sector that are moving higher following Harris&#8217;s comments, include Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) and Canopy Growth Corporation (NASADQ:CGC)
How To Buy Tilray Brands Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/markets/cannabis/24/09/41096880/gop-senator-leads-bipartisan-effort-to-seal-low-level-marijuana-possession-records-providing-sec">GOP Senator Leads Bipartisan Effort To Seal Low-Level Marijuana Possession Records, Providing &#8216;Second Chance&#8217;</a>
TLRY Price Action: At the time of writing, Tilray shares are trading 2.59% higher at $1.78, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo by noexcusesradio via Pixabay

What's Going On With Tilray Brands Stock Monday?

WIIM

Shares of cannabis stocks are trading higher following a report suggesting that Vice President Harris wants to legalize marijuana.

<a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/">https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/</a>
Vice President Kamala Harris says it's time to legalize marijuana—marking the first time she has publicly discussed her position on cannabis since becoming the Democratic presidential nominee.
"I just feel strongly, people should not be going to jail for smoking weed," she said in an interview with the All the Smoke podcast that was released on Monday. "And we know historically what that has meant and who has gone to jail."
"Second, I just think we have come to a point where we have to understand that we need to legalize it and stop criminalizing this behavior," Harris told hosts Matt Barnes and Stephen Jackson, who are former NBA players.
"Actually this is not a new position for me," Harris, who sponsored a federal cannabis legalization bill as a U.S. senator, said. "I have felt for a long time we need to legalize it. So that's where I am on that."
Until now, Harris had not made her position on marijuana part of her current campaign for the White House.
Earlier this month, <a href="https://www.marijuanamoment.net/marijuana-legalization-is-an-issue-for-the-states-vp-candidate-tim-walz-says-adding-that-electing-democrats-to-congress-will-boost-cannabis-reform/">Democratic vice presidential nominee Tim Walz said he thinks marijuana legalization is an issue that should be left to individual states</a>, adding that electing more Democrats to Congress could also make it easier to pass federal reforms like cannabis banking protections.
"I think it's an issue for the states on some of those, and that's the way the states have done it," Walz, who is Minnesota's governor and previously served in Congress, said, dodging a reporter's direct question about national cannabis legalization.
During that interview, Walz highlighted two incremental reform issues: medical marijuana access for veterans who receive healthcare through the Department of Veterans Affairs (VA) as well as passage of federal legislation that would ease restrictions for banks that due business with marijuana companies.
If Democrats take control of both houses of Congress, he said, those matters might be easier to address.
"There's work to be done nationally around the banking issue," he said in the Spectrum News&nbsp;interview&nbsp;that was posted on September 14, "and I think that's something that if we get a working Congress who actually wants to solve some issues—when we have the Democrats in charge of the House and the Senate—then we can start to see if some of those things make sense."
Harris, for her part, has spoken in favor of federal legalization in the past, for example at&nbsp;<a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-since-joining-biden-ticket-signaling-potential-shift-ahead-of-election/">a closed-door roundtable event with cannabis pardon recipients</a> in March. In her previous run for president, Harris also&nbsp;<a href="https://www.marijuanamoment.net/harris-backed-broad-drug-decriminalization-during-2020-election-run-resurfaced-aclu-questionnaire-shows/">backed full federal decriminalization for simple drug possession</a>.
Meanwhile former President Donald Trump said recently during his campaign for a second term that he now supports federal marijuana rescheduling and marijuana banking access.
"As President, we will continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug, and work with Congress to pass common sense laws, including safe banking for state authorized companies, and supporting states rights to pass marijuana laws, like in Florida, that work so well for their citizens," Trump posted to social media earlier this month.
<a href="https://www.marijuanamoment.net/trump-says-florida-marijuana-legalization-ballot-measure-will-be-very-good-for-the-state-adding-that-medical-use-is-absolutely-amazing-for-patients/">Trump also recently discussed the medical benefits</a>&nbsp;of cannabis and said legalization would be "very good" for Florida, which will consider the reform at the ballot box in November's election.
The Harris–Walz campaign, however, has&nbsp;<a href="https://www.marijuanamoment.net/harris-campaign-accuses-trump-of-lying-about-marijuana-reform-support-but-again-declines-to-detail-her-own-platform/">accused Trump of lying about his support for marijuana reform</a>—arguing that his "blatant pandering" runs counter to his administration's record on cannabis.
Following Trump's recent announcement of support for the Florida cannabis legalization ballot measure, the Democratic campaign has been working to remind voters that while in office, <a href="https://www.marijuanamoment.net/harris-accuses-trump-of-brazen-flip-flops-on-marijuana-as-former-president-endorses-florida-legalization-measure/">Trump "took marijuana reform backwards."</a>
In a memo from a senior campaign spokesperson, the Harris-Walz campaign accused Trump of "brazen flip flops" on cannabis, saying it's one of the Republican former president's "several bewildering ‘policy proposals' that deserve real scrutiny."
The posturing by the presidential candidates comes amid an ongoing process of moving marijuana to the less-restrictive Schedule III of the Controlled Substances Act (CSA).
The Department of Health and Humans Services (HHS) this spring recommended moving the drug to Schedule III, but the action has faced resistance from the Drug Enforcement Administration (DEA), which has&nbsp;<a href="https://www.marijuanamoment.net/dea-schedules-hearing-on-marijuana-rescheduling-proposal-delaying-final-rule/">scheduled a hearing on the proposal for December 2</a>—after the presidential election,&nbsp;<a href="https://www.marijuanamoment.net/dea-pushing-marijuana-rescheduling-past-election-is-incredibly-disappointing-congressman-says-as-stakeholders-react-to-hearing/">raising concerns that the process will not be completed</a>&nbsp;until after a new president is inaugurated.
Meanwhile, Trump also recently&nbsp;<a href="https://www.marijuanamoment.net/trump-claims-harris-jailed-thousands-and-thousands-of-black-people-over-marijuana-but-her-actual-record-as-a-prosecutor-is-more-nuanced/">went after Harris over her prosecutorial record on marijuana</a>, claiming that she put "thousands and thousands of Black people in jail" for cannabis offenses—but the full record of her time in office is more nuanced.
Trump's line of attack, while misleading, was nonetheless notable in the sense that the GOP presidential nominee implied that he disagrees with criminalizing people over marijuana and is moving to leverage the idea that Harris played a role in racially disproportionate mass incarceration.
As president, Trump largely stayed true to his position that marijuana laws should be handled at the state-level, with no major crackdown on cannabis programs as some feared after then-Attorney General Jeff Sessions rescinded the Obama era federal enforcement guidance. In fact, Trump&nbsp;<a href="https://www.marijuanamoment.net/gop-senator-reveals-what-trump-said-about-jeff-sessionss-anti-marijuana-moves/">criticized the top DOJ official and suggested the move should be reversed</a>.
While he was largely silent on the issue of legalization, he did tentatively endorse a bipartisan bill to&nbsp;<a href="https://www.marijuanamoment.net/trump-says-he-supports-senate-marijuana-legislation/">codify federal policy respecting states' rights to legalize</a>.
That said, on several occasions he released signing statements on spending legislation stipulating that he&nbsp;<a href="https://www.marijuanamoment.net/trump-issues-signing-statement-on-medical-marijuana-provision-of-funding-bill/">reserved the right to ignore a long-standing rider</a>&nbsp;that prohibits the Justice Department from&nbsp;<a href="https://www.marijuanamoment.net/trump-says-he-can-ignore-medical-marijuana-protections-passed-by-congress/">using its funds to interfere with state-legal medical marijuana programs</a>.
Before President Joe Biden bowed out of the race, his campaign made much of the president's mass cannabis pardons and rescheduling push,&nbsp;<a href="https://www.marijuanamoment.net/biden-smokes-trump-on-marijuana-policy-campaign-says-after-presidents-rescheduling-announcement/">drawing a contrast with the Trump administration's record</a>. The Harris campaign so far has not spoken to that particular issue, and the nominee has yet to publicly discuss marijuana policy issues since her own campaign launched.

Macro Economic Events

Politics

Econ #s

Economics

General

"Kamala Harris Says 'We Need To Legalize' Marijuana For First Time As Democratic Presidential Nominee" - Marijuana Moment

<a href="https://cannabiswire.com/news/2024/09/26/for-the-first-time-national-agriculture-regulators-group-grapples-with-cannabinoid-hemp/">https://cannabiswire.com/news/2024/09/26/for-the-first-time-national-agriculture-regulators-group-grapples-with-cannabinoid-hemp/</a>
&nbsp;

"National Agriculture Regulators Group Grapples With Intoxicating Hemp For The First Time; FDA's Norm Birenbaum Says Existing FDA Regulatory Frameworks 'Do Not Apply To Large Segments Of The Market, Like Inhalable Products, Where We Have Tremendous Concerns'" - Cannabis Wire

Canadian <a href="http://benzinga.com/cannabis">cannabis</a> powerhouse Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), announced Tuesday that it has launched a new line of hemp-derived Delta-9 THC beverages across key U.S. markets. 
The drinks, set to debut in October, include a range of mocktails, seltzers and sparkling beverages crafted with premium hemp extracts. This move marks Tilray's strategic expansion into the fast-growing <a href="https://www.benzinga.com/topic/cannabis-beverages">hemp-derived THC beverage</a> category.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Tilray Targets Growing Cannabis Beverage Market</h3>
Tilray, already a leader in the cannabis, <a href="http://benzinga.com/topic/hemp">hemp</a> and beverage industries, is leveraging its expertise to meet rising consumer demand for alternative adult beverages. Its new product lineup includes brands like 420 Fizz, Herb &amp; Bloom, Fizzy Jane's and Happy Flower, each with 5mg of Delta-9 THC per can. These products will target a variety of occasions and consumer price points, appealing to diverse audiences.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40509701/hemp-derived-thc-beverages-navigating-regulatory-uncertainty-in-a-potential-13-5b-market">Hemp-Derived THC Beverages: Navigating Regulatory Uncertainty In A Potential $13.5B Market</a>
<h3 class="wp-block-heading">Eyeing Broader Expansion In U.S.</h3>
Tilray's push into the Delta-9 THC space builds on its established presence in the hemp food and craft beer markets. As consumers explore <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40326384/budget-friendly-high-thc-beverages-the-untapped-niche-investors-cant-afford-to-miss">new adult beverage options</a>, the company aims to capture market share by offering a premium, responsibly formulated product experience.&nbsp;
The initial portfolio will roll out in states like <a href="http://benzinga.com/topic/texas-cannabis">Texas</a> and <a href="http://benzinga.com/topic/louisiana-cannabis">Louisiana</a>, with plans for future expansion.
TLRY Price Action TLRY's shares were trading 4.44% higher at $1.76 per share at the time of this writing around noon ET Tuesday.
Related News
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40956859/hemp-derived-products-like-delta-8-thc-are-here-to-stay-says-analyst">Hemp-Derived Products Like Delta-8 THC Are &#8216;Here To Stay,&#8217; Says Analyst</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40945349/cannabis-companies-have-missouris-governor-beat-hemp-thc-products-sales-resume-as-stricter-contr">Cannabis Companies Have Missouri&#8217;s Governor Beat: Hemp-THC Products Sales Resume As Stricter Controls Replace Sweeping Ban</a></li>
</ul>
Image courtesy of Tilray.

Retail Sales

Tilray Brands Launches Hemp-Derived Delta-9 THC Drinks In Key U.S. Markets

<a href="https://www.marijuanamoment.net/dea-calls-for-massive-increases-in-psilocybin-ibogaine-and-thc-manufacturing-this-year-to-meet-research-demands/">https://www.marijuanamoment.net/dea-calls-for-massive-increases-in-psilocybin-ibogaine-and-thc-manufacturing-this-year-to-meet-research-demands/</a>
The Drug Enforcement Administration (DEA) is proposing a dramatic increase in its 2023 production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to "support research and clinical trials" into the substances.
DEA wants to nearly double the amount of psilocybin, psilocyn and delta-9 THC that's manufactured compared to initial levels set for this year, while quintupling how much ibogaine is produced. It also wants 23 times as much of "other tetrahydrocannabinol," raising the quota from 15,000 grams to 350,000 grams for 2023.
The agency had already increased its initial quota for various controlled substances, including cannabis and psychedelics, late last year when it finalized the numbers. But now, in a notice published in the Federal Register on Tuesday, DEA said that more significant changes are warranted.
For psilocybin, the proposed new quota is 15,000 grams, rather than 8,000 grams as previously set for 2023. DEA also wants 24,000 grams of the psychedelic compound psilocyn, double its prior 12,000-gram quota.
The now-increased initial 2023 levels for both of the "magic mushroom" components already represented significant increases from those set for prior years, demonstrating the ongoing heightened level of interest in researching psychedelics over time.
DEA is also proposing to manufacture 150 grams of ibogaine—five times the amount it called for in December 2022.
While the agency didn't change its 6.7 million-gram quota for marijuana for the year, it is now calling for the manufacturing of 628,460 grams of delta-9 THC, rather than 384,460 grams—a 63 percent increase.
For all other tetrahydrocannabinol, DEA wants 350,000 grams, a notable increase from its prior 15,000-gram quota—a massive 2,233 percent increase.
The proposed increases, which are subject to a 30-day public comment period starting on Tuesday, comes in the context of an ongoing administrative review into the scheduling status of cannabis that DEA is actively carrying after receiving a recommendation from the U.S. Department of Health and Human Services (HHS) to <a href="https://www.marijuanamoment.net/top-federal-health-agency-releases-highly-redacted-marijuana-scheduling-recommendation-letter-to-dea/">move marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA)</a>.
It also comes as experts await a <a href="https://www.marijuanamoment.net/after-latest-clinical-trial-mdma-therapy-for-ptsd-is-on-track-for-fda-consideration-next-year/">potential federal approval for certain psychedelics like psilocybin and MDMA</a> as therapeutics for the treatment of serious mental health conditions.
The updated quotas reflect "the estimated medical, scientific, research, and industrial needs of the U.S., for lawful export requirements, and for the establishment and maintenance of reserve stocks," DEA <a href="https://www.federalregister.gov/public-inspection/2023-23931/proposed-adjustments-to-the-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances">said</a> in its new quota increase notice.
"DEA is proposing increases to the [aggregate production quotas] for the following schedule I substances: all other tetrahydrocannabinol, delta-9-tetrahydrocannabinol, ibogaine, psilocybin, and psilocyn," it said. "These proposed increases are to support research and clinical trials by DEA-registered schedule I researchers. These proposed increases demonstrate DEA's support for research with schedule I controlled substances."
 DEA's prior "final" quotas that were published late last year already <a href="https://www.marijuanamoment.net/dea-proposes-dramatic-increases-in-marijuana-and-psychedelics-production-in-2023-for-research/">contained increases compared to its initial proposal</a>, with <a href="https://www.marijuanamoment.net/dea-proposes-even-higher-2023-production-quotas-for-psychedelics-like-mdma-and-psilocyn/">the agency calling for the manufacturing of more psychedelic compounds</a> such as MDMA, psilocyn and 5-MeO-DMT.
This year's 6.7 million-gram quota for marijuana is more than double DEA's final <a href="https://www.marijuanamoment.net/dea-again-boosts-2022-production-goals-for-psychedelics-like-psilocybin-mdma-and-dmt/">cannabis quota for 2022, which was 3.2 million grams.</a>&nbsp;<a href="https://www.marijuanamoment.net/dea-boosts-psilocybin-mdma-and-dmt-production-levels-again-in-final-quotas-for-2021/">It was 2 million grams for 2021</a>.
Growing millions of grams of cannabis may be easier since&nbsp;<a href="https://www.marijuanamoment.net/dea-finally-breaks-federal-marijuana-grower-monopoly-with-two-new-companies-harvesting-cannabis-approved-by-agency/">DEA finally authorized additional manufacturers</a>&nbsp;at the beginning of the year. Those approved cultivators are now able to apply for&nbsp;<a href="https://www.marijuanamoment.net/top-federal-drug-agency-seeking-marijuana-grower-able-to-cultivate-and-analyze-4-million-grams-of-cannabis/">a contract to be federal marijuana suppliers</a>&nbsp;for study purposes under the National Institute on Drug Abuse (NIDA).
The agency has touted its Schedule I drug production quotas as evidence that is supports rigorous research into the substances, but it's faced criticism from advocates and scientists over actions that are viewed as antithetical to promoting studies.
Following pushback, DEA recently retreated on&nbsp;<a href="https://www.marijuanamoment.net/dea-abandons-proposal-to-ban-two-more-psychedelics-after-being-challenged-by-scientists/">a proposed ban on psychedelic compounds</a>&nbsp;that scientists say have research value.
That marked another win for scientific community, coming just one month after DEA&nbsp;<a href="https://www.marijuanamoment.net/dea-cancels-proposed-ban-of-five-psychedelics-giving-scientists-more-time-to-research-therapeutic-benefits/">abandoned separate plans to place five tryptamine psychedelics in Schedule I</a>.
Meanwhile, a federal appeals court recently ruled against DEA in a <a href="https://www.marijuanamoment.net/federal-appeals-court-rules-against-dea-in-psilocybin-rescheduling-lawsuit-brought-by-doctor-who-wants-to-give-psychedelic-to-cancer-patients/">lawsuit over a Washington State doctor's petition to reschedule psilocybin</a>. The court said DEA failed to explain its reasoning when it denied the petition, and it ordered the agency to provide a more complete justification.
With respect to the agency's marijuana scheduling review, a coalition of 31 bipartisan House lawmakers has sent a letter to DEA Administrator Anne Milgram, urging her to <a href="https://www.marijuanamoment.net/31-bipartisan-house-lawmakers-push-dea-to-consider-merits-of-marijuana-legalization-as-it-completes-scheduling-review/">take into account congressional and state marijuana legalization efforts</a> as it completes that assessment. They also criticized the limitations of simple rescheduling as they push for complete a complete removal of marijuana from the CSA.
The letter serves as a counterbalance to other recent messages DEA has received from congressional opponents of reform and former DEA and White House drug czars who&nbsp;<a href="https://www.marijuanamoment.net/marijuana-rescheduling-would-supersize-the-industry-former-dea-heads-and-white-house-drug-czars-warn-biden-administration/">argue that even moving marijuana to Schedule III would go too far</a>.
A coalition of 14 Republican congressional lawmakers recently&nbsp;<a href="https://www.marijuanamoment.net/14-gop-congressional-lawmakers-tell-dea-to-keep-marijuana-in-schedule-i-and-reject-top-health-agencys-recommendation/">urged DEA to "reject" the top federal health agency's recommendation to reschedule marijuana</a>&nbsp;and instead keep it in the most restrictive category under the CSA.
Meanwhile, two GOP senators, including the lead Republican sponsor of&nbsp;<a href="https://www.marijuanamoment.net/watch-live-a-u-s-senate-committee-is-voting-on-a-marijuana-banking-bill/">a marijuana banking bill that cleared a key committee last month</a>, recently filed new legislation to&nbsp;<a href="https://www.marijuanamoment.net/gop-senators-file-bill-to-block-biden-marijuana-rescheduling-effort-without-congressional-approval/">prevent federal agencies from rescheduling cannabis&nbsp;without tacit approval from Congress</a>.

Biotech

CMPS

CYBN

DRUG

ENVB

MNMD

SEEL

'DEA Calls For Massive Increases In Psilocybin, Ibogaine And THC Manufacturing This Year To Meet Research Demands'  - Marijuana Moment

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 1491.67% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 42.26% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 22.73% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 18.97% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 16.58% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 11.52% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 4.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.95% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/OGI">OrganiGram Holdings</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 3.26% at $1.80</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 3.05% at $0.17</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 61.70% at $19.51</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 31.03% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 18.03% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 13.85% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 10.27% at $2.95</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 10.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 9.18% at $0.85</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 7.76% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 5.76% at $1.31</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 5.50% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 5.12% at $2.04</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed down 4.94% at $0.51</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 4.76% at $1.99</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 4.59% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 3.53% at $10.67</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.38% at $1.72</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 3.33% at $0.47</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 3.15% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 3.02% at $11.04</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLGVF

BMMJ

CNTMF

CPHRF

EAST

FUAPF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

MRMD

NWVCF

OILFF

RMHB

TCNNF

Cannabis Stock Movers For September 20, 2024

Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>) announced on Wednesday the launch of Redecan EU-GMP certified medical <a href="https://www.benzinga.com/topic/australia">cannabis products in Australia</a>.
What Happened: The following&nbsp;Redecan&nbsp;products are now available for medical cannabis patients in&nbsp;Australia, including:
<ul>
<li>Redecan PC THC28 Purple Churro – 15g</li>
<li>Redecan SA THC28 Space Age Cake – 15g</li>
</ul>
Why It Matters: Denise Faltischek, chief strategy officer and head of international at Tilray Brands, praised the move.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/22/08/28597648/tilrays-cbd100-approved-for-clinical-trials-in-australia-and-new-zealand-by-the-natural-health-s">Tilray&#8217;s CBD100 Approved For Clinical Trials In Australia And New Zealand By The Natural Health Science Foundation</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
"The launch of Redecan further expands our medical cannabis portfolios alongside our current Tilray and Broken Coast offerings, as we continue our mission of empowering patients and healthcare practitioners to find the optimal therapeutic solutions," Faltischek said.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18084431/ccc-oct-24-banner__1_-26.gif" alt="" class="wp-image-553913" /></a></figure>
Jonathan Trodden, director at Tilray Medical Australia, agrees: "We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of premium quality medical cannabis to choose from.&#8221;
Tilray has been present in Australia for years. In 2022, the company launched a new medical cannabis e-learning platform for healthcare providers, built on the importance of understanding the benefits derived <a href="https://www.benzinga.com/markets/cannabis/22/01/25204825/tilray-expands-medical-marijuana-product-offering-in-australia-launches-cannabis-e-learning-plat">from medical cannabis use</a>. This effort followed Tilray&#8217;s successful introduction of multiple medical cannabis workshops across Australia and New Zealand, educating hundreds of healthcare practitioners in 2021.
Price Action: Tilray's shares traded 0.51% higher at $1.8193 per share during the pre-market session on Wednesday morning.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37706111/weed-giants-tilray-and-curaleaf-ramp-up-presence-in-europe-heres-why">Weed Giants Tilray And Curaleaf Ramp Up Presence In Europe, Here&#8217;s Why</a></li>
</ul>

TSX:TLRY

Cannabis Giant Tilray Expands Medical Marijuana Portfolio With Redecan Launch In Australia

Tilray Medical Announced The Launch Of Redecan EU-GMP Certified Medical Cannabis Products In Australia

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) agreed to acquire a promissory note from Ontario-based Double Diamond Holdings Ltd (DDH) for $23.8 million, according to a regulatory filing.
DDH is a joint venture with Aphria Inc., Tilray's direct and wholly-owned subsidiary, in Aphria Diamond.
In return, Tilray issued 13,217,588 shares of its common stock at $0.0001 per share to DDH.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17095856/ccc-oct-24-banner__1_-1-10.gif" alt="" class="wp-image-551931" /></a></figure>
The company said no underwriter took part in the offer and sale of the consideration shares, and no commission or other remuneration was paid or given directly or indirectly in connection with the deal.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Read Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40036301/tilray-should-be-a-long-term-holding-in-any-global-portfolio-of-cannabis-stocks-say"> ‘Tilray Should Be A Long-Term Holding In Any Global Portfolio Of Cannabis Stocks,&#8217; Says Analyst</a>
<h3 class="wp-block-heading">Tilray's Craft Beer Business</h3>
The news comes on the heels of Tilray's announcement that it has completed the <a href="https://www.benzinga.com/markets/cannabis/24/08/40365052/billion-dollar-cannabis-firm-buys-a-brewery-four-actually-in-canadas-backyard">previously announced</a> acquisition of Atwater Brewery, from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>). Atwater Brewery was one of four craft breweries Tillray previously said it would acquire. The medical cannabis giant acquired Hop Valley Brewing Company, Terrapin Beer Co., and Revolver Brewing, in early September.
The acquisition bolstered Tilray's leadership position in the U.S. craft beer market as the 5th largest craft brewer in the country and the top craft brewer in the Pacific Northwest and Georgia. Tilray is based in Canada.
Known for brands like SweetWater Brewing and Montauk Brewing Company, Tilray earlier said it expects a 30% growth in its <a href="https://www.benzinga.com/markets/cannabis/23/09/34579077/tilrays-beer-business-expands-nationally-starting-in-this-state">beer business from this acquisition.</a>
Irwin D. Simon, the company's chairman and CEO, praised the move. &#8220;This strategic acquisition creates additional growth opportunities for our global beverage business, which reinforces our commitment to enhancing shareholder value,&#8221; he said.
Price Action: Tilray&#8217;s shares traded 1.11%% higher at $1.8199 per share at the time of writing on Tuesday morning.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39539050/is-tilrays-2b-valuation-just-the-beginning-analyst-sees-10b-market-opportunity-initiates-coverag">Is Tilray Really Worth $2B? Analysts See Path To $10B Market Opportunity</a></li>
</ul>
Photo: Courtesy of Kindel Media by Pexels

Financing

Tilray Acquires $23.8M Promissory Note In Deal With Double Diamond On Heels Of Brewery Acquisition

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 38.20% at $5.91</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 20.09% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 13.92% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 13.33% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 7.28% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed up 6.11% at $0.59</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 4.32% at $10.78</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 4.04% at $1.40</li>
<li><a href="https://www.benzinga.com/quote/GENE">Genetic Technologies</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed up 3.62% at $0.82</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 3.45% at $1.80</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 28.57% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 20.05% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 15.10% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 14.29% at $0.0006</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 9.09% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 8.27% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 8.24% at $0.32</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 5.60% at $2.35</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.46% at $53.88</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GENE

GNLN

GTBIF

KAYS

Marijuana Stock Movers For September 16, 2024

The Czech Republic could be missing out on hundreds of millions of euros annually as the governing coalition remains persistent in avoiding establishing a regulated marijuana market. That's according to the findings of a comprehensive study examining the possible costs and benefits of various cannabis reform models being proposed nationwide.
<h3 class="wp-block-heading">What Happened</h3>
The researchers from the Faculty of Business Economics at the University of Prague concluded that a &#8220;comprehensive model,&#8221; incorporating self-cultivation, cannabis clubs and a fully commercial market, could result in "total net social benefits of CZK 5.5 billion (218 million euros; $242 million) per year," <a href="https://businessofcannabis.com/new-study-backs-full-cannabis-legalisation-in-czech-republic-projecting-czk-5-5bn-in-social-benefits-annually/">reported</a> Business of Cannabis.
The study was published on Thursday, Sept. 12, by the University of Prague. It analyzed each of the cannabis reform models proposed by former National Drug Coordinator Jindřich Vobořil.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16093721/ccc-oct-24-banner__1_-22.gif" alt="" class="wp-image-549705" /></a></figure>
Vobořil left his position this summer, but he continued taking part in the development of addiction policies in the country as an <a href="https://www.benzinga.com/markets/cannabis/24/07/39915786/leaked-document-reveals-czechias-plans-for-cannabis-legalization">independent expert.</a> He previously completed two separate versions of the measure to legalize cannabis.
Vobořil's legislation, which includes commercial sales, seeks to set up a cannabis market <a href="https://www.benzinga.com/markets/cannabis/24/07/39773667/leaked-documents-czech-republic-plans-to-set-up-legal-recreational-cannabis-market">much like that in Canada and certain US states.</a> The other measure mimics Germany's current cannabis framework, with legal home cultivation and cannabis social clubs.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40626067/full-cannabis-legalization-not-yet-off-the-table-in-czech-republic-some-lawmakers-want-only-home">Full Cannabis Legalization Not Yet Off The Table In Czech Republic, Some Lawmakers Want Only Home Grow</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Which Legalization Model Is Most Economically Advantageous?</h3>
That said, the study suggested that legalizing only self-cultivation would yield a net social benefit of CZK 1.2 billion annually and CZK 16.5 billion over the first 11 years. Moreover, putting cannabis clubs into the equation would result in CZK 1.5 billion per year and CZK 20.8 billion over 11 years in social benefits.
However, the highest returns would come from the comprehensive model, featuring a regulated market alongside self-cultivation and clubs, which is projected to deliver CZK 5.5 billion per year and CZK 77.2 billion over 11 years in social benefits.
"The conclusions are very simple,&#8221; Patrik Sieber, one of the study's authors, said. &#8220;All evaluated options appear to be socially and financially more beneficial for public budgets than maintaining the status quo.&#8221;
<h3 class="wp-block-heading">These Cannabis Operators Could Benefit From Policy Change</h3>
In the meantime, cannabis operators have been strengthening their market presence in the European country.
Curaleaf International, part of Curaleaf Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), already present in the European market, opted to expand in the Czech Republic in March, via a new <a href="https://www.benzinga.com/markets/cannabis/24/03/37706111/weed-giants-tilray-and-curaleaf-ramp-up-presence-in-europe-heres-why">supply agreement with Astrasana Pharma s.r.o.</a> Under that deal, Curaleaf International's EU-GMP flower was made available to patients via Pilulka Pharmacy, a healthcare provider in the region.
PharmaCielo Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PCLOF#OTC">PCLOF</a>)'s first shipment of THC-dominant dried cannabis flower to a customer in the Czech Republic <a href="https://www.benzinga.com/markets/cannabis/22/09/28882197/pharmacielo-ships-dried-cannabis-flower-to-the-czech-republic-expanding-its-exports-to-eu">made headlines in 2022.</a>
In 2023, the medical cannabis division of Canadian giant Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) expanded its European footprint across the Czech Republic through a new export and distribution <a href="https://www.benzinga.com/markets/cannabis/23/10/35162207/canopy-growth-shares-up-slightly-in-pre-market-trading-on-eu-gmp-certification-news">partnership with Cansativa Group.</a>
Additionally, Canopy Growth Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>)&#8217;s medical brands already service European medical markets in Germany, the Czech Republic and Poland as well as Asia-Pacific markets including <a href="https://www.benzinga.com/markets/cannabis/23/10/35162207/canopy-growth-shares-up-slightly-in-pre-market-trading-on-eu-gmp-certification-news">Australia and New Zealand</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39442869/2-9b-european-cannabis-market-a-strategic-blueprint-for-cross-border-transportation-logistics">$2.9B European Cannabis Market: A Strategic Blueprint For Cross-Border Transportation Logistics</a></li>
</ul>

Education

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

PCLOF

TSX:WEED

WEED

This European Country Could Lose $242M A Year If It Doesn't Regulate Its Marijuana Market, Study Finds

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) confirmed Thursday it has completed the <a href="https://www.benzinga.com/markets/cannabis/24/08/40365052/billion-dollar-cannabis-firm-buys-a-brewery-four-actually-in-canadas-backyard">previously announced</a> acquisition of Atwater Brewery, from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>).
&#8220;Atwater Brewery is a renowned craft brewery with a rich history and a loyal following in Michigan," said Irwin D. Simon, chairman and chief executive officer of Tilray Brands. "This acquisition expands our reach in the Great Lakes region and further strengthens our position in the craft beer industry. We are excited to welcome Atwater Brewery to Tilray Brands and are committed to leveraging our expertise and resources to drive growth, expand distribution, and provide beer lovers with access to Atwater&#8217;s exceptional brews."
TD Securities acted as financial advisor, and DLA Piper LLP (US) acted as external legal counsel to Tilray Brands.
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out
The Atwater Brewery acquisition comes on the heels of finalized purchases of craft breweries Hop Valley Brewing Company, Terrapin Beer Co., and Revolver Brewing, also from Molson.
Over the last several months, Tilray, <a href="https://www.benzinga.com/markets/cannabis/24/06/39539050/is-tilrays-2b-valuation-just-the-beginning-analyst-sees-10b-market-opportunity-initiates-coverag" target="_blank" rel="noreferrer noopener">valued</a> at $2 billion, has been expanding its U.S. brewery business but is not giving up on cannabis. In August, it <a href="https://www.benzinga.com/markets/cannabis/24/08/40510926/tilray-is-not-giving-up-on-cannabis-ramps-up-its-canadian-portfolio-on-heels-of-buying-four-us-b">released its latest small-batch flower strain</a>, Milk &amp; Cookies, under its premium cannabis brand Broken Coast, and in September, it published the results of a study focused on cannabis as a potential treatment for pain management and <a href="https://www.benzinga.com/markets/cannabis/24/09/40774179/cannabinoid-treatment-significantly-reduces-fibromyalgia-pain-and-improves-quality-of-life-new-t">other fibromyalgia-associated symptoms</a>.
Moreover, the Canadian cannabis giant is also working on expanding its medical marijuana business globally and has <a href="https://www.benzinga.com/markets/cannabis/24/08/40325566/these-3-cannabis-companies-hold-cultivation-licenses-in-germany-a-1-8b-market-opportunity" target="_blank" rel="noreferrer noopener">already obtained a cultivation license</a> in Germany, whose market is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37896976/cannabis-stocks-set-to-dominate-germanys-new-market-a-surge-in-demand-meets-establi" target="_blank" rel="noreferrer noopener">projected</a> to reach a valuation of approximately €1.7 billion ($1.86 billion) by 2025​.
Tilray Brands' beverage portfolio includes famed craft beer, spirits and non-alcohol beverage brands such as SweetWater Brewing Company, Montauk Brewing Company, Alpine Beer Company, Green Flash Brewing Company, Shock Top, Breckenridge Brewery, Breckenridge Distillery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewing Company, Widmer Brothers Brewing, Square Mile Cider Company, HiBall Energy, Happy Flower CBD along with Canada&#8217;s top recreational cannabis and THC beverage brands Mollo and XMG.
Price Action: Tilray shares closed Thursday's market session 1.16% lower at $1.70 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39539050/is-tilrays-2b-valuation-just-the-beginning-analyst-sees-10b-market-opportunity-initiates-coverag">Is Tilray Really Worth $2B? Analysts Sees Path To $10B Market Opportunity</a></li>
</ul>
Photo: Courtesy of Lucas via Pexels

Billion-Dollar Marijuana Giant Buys Another Brewery From Molson Coors, Expands Great Lakes Footprint

Tilray Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NYSE">TLRY</a>) short percent of float has fallen 6.2% since its last report. The company recently reported that it has 101.55 million shares sold short, which is 12.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tilray Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726166716_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tilray Brands has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Tilray Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tilray Brands's peer group average for short interest as a percentage of float is 19.42%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(TLRY) - Analyzing Tilray Brands's Short Interest

SNDL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) announced on Tuesday that Taranvir &#8220;Tank&#8221; Vander, president of its Liquor Division, is stepping down after two decades of leadership in the liquor industry. Vander, who began his career as a liquor store manager in the early 2000s, is retiring to pursue new opportunities.
In 2013, Vander founded Ace Liquor Corporation, expanding it to 15 stores. In 2019, he joined forces with Alcanna Inc., helping it become one of Canada's largest liquor retailers. Zachary George, CEO of SNDL, thanked Vander for his contributions. "We want to thank Tank for his exceptional leadership and wish him continued success in his future endeavors."
Navroop Sandhawalia, VP of finance for Liquor Retail at SNDL, <a href="https://www.prnewswire.com/news-releases/sndl-announces-departure-of-liquor-segment-president-302244048.html#:~:text=CALGARY%2C%20AB%2C%20Sept.%2010,SNDL%20to%20pursue%20new%20opportunities">will take over</a> as interim president of the liquor division while the company searches for a permanent replacement.
Get Benzinga&#8217;s exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">SNDL Stock Performance Compared To Other Canadian Cannabis Companies</h3>
After the market closed on Tuesday, September 10, 2024, SNDL experienced a slight dip in its stock price, closing at $2.10, down 0.47%. Trading volume for SNDL reached 1,697,281 shares, reflecting continued investor activity as the company transitions leadership in its Liquor Division.
In comparison, other notable <a href="https://www.benzinga.com/topic/canada-cannabis">Canadian cannabis stocks</a> also saw mixed results:
<ul>
<li>Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) closed at $5.55, down 1.56%, with 568,615 shares traded. Despite a lower percentage drop than SNDL, Aurora's stock showed greater volatility with a day high of $5.90 and a low of $5.55.</li>
<li>OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) fared slightly better, closing at $1.83, up 1.1%. The stock saw a trading volume of 297,194 shares, indicating moderate investor interest.</li>
<li>Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) closed at $1.69, down 0.59%, with a significant trading volume of 18,592,650 shares, reflecting heightened activity compared to other stocks.</li>
<li>High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) showed positive momentum, increasing by 3.3% to close at $2.13, with 447,671 shares traded, positioning it among the stronger performers in the sector today.</li>
<li>Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) closed at $4.84, down 1.03%, with a volume of 2,777,417 shares. Despite the decline, Canopy saw considerable trading activity, suggesting continued investor engagement.</li>
</ul>
Overall, <a href="https://www.benzinga.com/markets/cannabis/24/08/40631613/sndl-wins-bid-for-indiva-secures-major-deal-to-boost-cannabis-edibles-market-share-in-canada">SNDL's performance </a>was relatively stable compared to its peers, with many Canadian cannabis stocks experiencing minor fluctuations throughout the trading day. The trading volumes across the sector reflected ongoing interest but no significant market shifts following the day&#8217;s developments.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40783919/cannabis-flower-no-thanks-canadians-shift-to-pre-rolls-vapes-as-market-eyes-c-5-47b">Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls &amp; Vapes As Market Eyes C$5.47B</a>

Management

 CGC

HITI

Last Call For SNDL's Liquor President: Stock On The Rocks Amid Leadership Changes

The latest equity research report from Pablo Zuanic of Zuanic &amp; Associates highlights key trends in Canada's cannabis market, noting a deceleration in recreational sales growth.
Data from StatCan reveals that sales for 2Q24 were down 4% year-over-year (YoY), contributing to a 1.3% decline year-to-date (YTD) compared to 14% growth in 1H23. In contrast, Hifyre data shows a 6% YTD growth through August.
If annualized, this growth would project a total<a href="https://www.benzinga.com/topic/canada-cannabis"> recreational market</a> size of C$5.47 billion for calendar year 2024, translating to US$102 per capita.
Get Benzinga&#8217;s exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Market Share Shifts Among Top Players</h3>
<a href="https://www.benzinga.com/topic/pablo-zuanic">Zuanic&#8217;s report </a>highlights notable shifts in market share among the top licensed producers (LPs). Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), once a dominant player, saw its share drop by 1.5 percentage points to 9.6% in August, continuing its decline over recent quarters. Decibel (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) also experienced a decline, dropping 0.9 percentage points to 5.2%.
Meanwhile, Village Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) experienced strong growth, increasing its market share to 7.9%, up from 6.1% a year ago, representing a 34% year-over-year growth. Similarly, Cronos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) and Organigram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) posted gains, with Cronos maintaining a steady 5.3% share (up 24% YoY), and Organigram growing its market share to 7.2%, up from 6.6% a year ago, reflecting 15% (YoY) growth.
Additionally, Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) and Cannara Biotech (unlisted) gained 0.5 points each, reaching 5.2% and 3.4% market shares, respectively.
Here is a breakdown of the major players:
<ul>
<li>Village Farms: sales grew +34% YoY, holding a 7.9% market share in August (up from 6.1% a year ago).</li>
<li>Cronos: +24% YoY growth in sales, maintaining a 5.3% share, consistent with previous quarters.</li>
<li>Organigram: +15% YoY growth in sales, with a market share of 7.2% in August, up from 6.6% a year ago.</li>
<li>Tilray: -20% YoY decline in sales, with a 9.6% market share in August, down from 10.1% earlier in the quarter.</li>
<li>Decibel: -25% YoY decline in sales, holding a 5.3% market share, down from 7.4% a year ago.</li>
</ul>
<h3 class="wp-block-heading">Format Preferences Continue To Evolve</h3>
The Canadian cannabis market is shifting towards newer product formats, with some segments outperforming others. Flower remains the largest category, accounting for 36% of sales in June-August 2024, down from 41% in 1Q23 and 57% in 1Q21. This decline reflects changing consumer preferences, as <a href="https://www.benzinga.com/markets/cannabis/24/06/39508155/900-pre-rolls-per-hour-upgrade-from-manual-to-automatic-speeds-up-joint-production-enhances-marg">pre-rolls</a> and vapes gain market share.
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34625368/nasa-precision-meets-cannabis-roi-pre-rolled-infusion-robots-revolutionizing-indust">Pre-rolls</a> now represent 34% of total sales, up from 27% in 1Q23 and 17% in 1Q21. The segment grew 11% year-over-year (YoY) in the June-August period, driven by consumer demand for convenience. Decibel leads with a 10.4% share, though it fell to 9.7% in August. Tilray holds 8.3%, and Organigram has 6.4%.
<a href="https://www.benzinga.com/general/biotech/24/08/40341814/tony-starks-choice-vape-synergy-innovations-strategic-move-to-restore-brands-identity-lead-market">Vapes </a>account for 16% of sales, up from 15% in 1Q22 and 14% in 1Q21, supported by 8% yoy growth. Motif Labs leads with 20.6%, followed by Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) at 12.4%, up from 10.7% in 2Q24.
Other formats, like concentrates, edibles, beverages, and oils, hold smaller shares. Concentrates and edibles each represent 5%, while <a href="https://www.benzinga.com/topic/cannabis-beverages">beverages </a>and oils account for 2% each. Concentrates grew 5% YoY, while edibles declined by 5%. Beverages saw a 6% YoY increase, indicating gradual consumer adoption.
Read Next: S<a href="https://www.benzinga.com/markets/cannabis/24/08/40631613/sndl-wins-bid-for-indiva-secures-major-deal-to-boost-cannabis-edibles-market-share-in-canada">NDL Wins Bid For Indiva, Secures Major Deal To Boost Cannabis Edibles Market Share In Canada</a>

Analyst Color

Market Summary

Analyst Ratings

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

TSXV:DB

Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls & Vapes As Market Eyes C$5.47B

Former President Donald Trump announced on Sunday night that, if re-elected, he would reschedule cannabis and support banking reforms for the marijuana industry. He also confirmed his support for Florida's Amendment 3, which would legalize recreational cannabis in the state. Trump's <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">comments</a> sparked a reaction in the cannabis stock market on Monday.
Get Benzinga's exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h3 class="wp-block-heading">Stocks Reaction</h3>
<ul>
<li>Trulieve Cannabis (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>): The price at market close was $10.99 with a change of +$1.28 (+13.18%). Trading volume reached 707,392, with a market cap of $2.06 billion.</li>
<li>Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>): The price at market close was $10.66 with a change of +$1.02 (+10.58%). Trading volume hit 473,092, with a market cap of $2.52 billion.</li>
<li>Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>): The price at market close was $3.10 with a change of +$0.26 (+9.15%). Trading volume reached 639,920, and the market cap stood at $2.09 billion.</li>
<li>Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>): The price at market close was $4.86 with a change of +$0.38 (+8.54%). Trading volume was 6,041,892, with a market cap of $412 million.</li>
<li>Sundial Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>): The price at market close was $2.14 with a change of +$0.16 (+8.08%). Trading volume hit 1,946,306, and the market cap was $530 million.</li>
<li>Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>): The price at market close was $5.80 with a change of +$0.39 (+7.25%). Trading volume was 1,136,294, with a market cap of $317 million.</li>
<li>Cronos Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>): The price at market close was $2.21 with a change of +$0.07 (+3.27%). Trading volume reached 1,448,055, with a market cap of $847 million.</li>
<li>HEXO Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEXO#NASDAQ">HEXO</a>): The price at market close was $1.35 with a change of +$0.05 (+3.85%). Trading volume was 1,215,840, with a market cap of $401 million.</li>
<li>AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>): The price at market close was $7.16 with a change of +$0.75 (+11.70%). Trading volume hit 13,998,304.</li>
<li>Innovative Industrial Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>): The price at market close was $122.69 with a change of +$2.02 (+1.67%). Trading volume was 90,181, with a market cap of $3.42 billion.</li>
<li>GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>): The price at market close was $1.92 with a change of +$0.05 (+2.96%). Trading volume hit 454,306, and the market cap was $110 million.</li>
<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>): The price at market close was $52.48 with a change of +$2.43 (+4.87%). Trading volume was 153,424, with a market cap of $630 million.</li>
<li>AdvisorShares Pure Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>): The price at market close was $3.35 with a change of +$0.21 (+6.69%). Trading volume reached 37,519.</li>
<li>Scotts Miracle-Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>): The price at market close was $67.62 with a change of -$0.20 (-0.29%). Trading volume reached 323,540, with a market cap of $3.85 billion.</li>
<li>Village Farms International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>): The price at market close was $1.01 with a change of +$0.01 (+1.02%). Trading volume hit 459,136, and the market cap was $113 million.</li>
<li>Trees (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CANN#OTC">CANN</a>): The price at market close was $0.042 with a change of -$0.012 (-22.22%). Trading volume was 118,407.</li>
<li>Medical Marijuana (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MJNA#OTC">MJNA</a>): The price at market close was $0.001 with no change. Trading volume hit 9,393,761, with a market cap of $5.68 million.</li>
<li>OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>): The price at market close was $1.83 with a change of +$0.08 (+4.29%). Trading volume was 348,054, with a market cap of $186 million.</li>
<li>High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>): The price at market close was $2.12 with a change of +$0.16 (+8.16%). Trading volume hit 648,008, with a market cap of $162 million.</li>
<li>Planet 13 Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNHF#OTC">PLNHF</a>): The price at market close was $0.96 with no significant change. Trading volume was 275,004.</li>
<li>Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>): The price at market close was $1.74 with a change of +$0.13 (+7.74%). Trading volume hit 438,517, with a market cap of $565 million.</li>
</ul>
<h3 class="wp-block-heading">Highs And Lows In 2024&nbsp;</h3>
The cannabis market has experienced several significant stock movements in recent months. On April 30, 2024, stocks soared after the DEA announced plans to reschedule cannabis to Schedule III, with Canopy Growth <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38536953/cannabis-stocks-react-to-dea-rescheduling-canopy-aurora-surge-tilray-wm-tech-hold-s">jumping</a> by 78.8% and Aurora Cannabis rising 46%. 
However, two weeks ago, following the DEA's decision to delay its final ruling, the sector saw a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40580306/cannabis-stocks-plummet-by-up-to-16-on-dea-rescheduling-delay-could-this-be-the-buy">sharp decline</a>, with Curaleaf falling 15.68% and Green Thumb Industries dropping 10.15%. In contrast, Monday's gains following Trump's support for Amendment 3 were more modest, with a mean growth of 4.31%, suggesting a recovery but not on the same scale as the April surge.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40776937/trump-joins-millions-of-americans-who-support-rescheduling-cannabis-weed-industry-responds-to-fo">Trump &#8216;Joins Millions Of Americans&#8217; Who Support Rescheduling Cannabis: Weed Industry Responds To Former Pres&#8217; News</a>

ETFs

CANN

CRLBF

HEXO

IIPR

MJNA

PLNHF

YOLO

Cannabis Stocks React To Trump's Marijuana Comments: See Which Ones Posted Solid Gains

If you are wary of the volatility of cannabis stocks then consider the 5 tobacco, beer, and distiller/vintner companies that have major investments in the cannabis sector. Their stock returns outperformed both our MSO and LP cannabis portfolios.

Our Conservative "Cannabis" Portfolio Performed Better In August (and YTD) Than Either OUR MSO Or LP Portfolios

If you are wary of the volatility of cannabis stocks then consider the 5 tobacco, beer, and distiller/vintner companies that have major investments in the cannabis sector.

Our Conservative "Cannabis" Portfolio Performed Better In August (And YTD) Than Either Our MSO Or LP Portfolios

Look For Tilray To Keep Declining

Our LP portfolio was down 10% last week as a result of the August 26th announcement by the DEA that it had scheduled an administrative hearing for December 2nd to consider differing expert opinions on the proposal that cannabis be re-classified.

Canadian Cannabis LP Stocks Portfolio -10% W/e Sept. 6th

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tilray (TLRY – Research Report) and Y-Mabs Therapeutics (YMAB – R...

Analysts Offer Insights on Healthcare Companies: Tilray (TLRY) and Y-Mabs Therapeutics (YMAB)

Tilray Brands Will Continue To Trend Lower

The Canadian Cannabis LP Stocks Portfolio was up +6% last week from a 10% decline w/e Sept. 6th as the negative sentiment waned surrounding the DEA's announcement that it would be having a December 2nd hearing to consider additional opinions

Cannabis LP Stocks Were +6% Last Week Vs. -10% The Previous Week

Our Conservative Cannabis Stocks Portfolio has outperformed our Canadian Cannabis LP Stocks Portfolio by more than a 3 to 1 margin on an annual basis. As such, our conservative cannabis portfolio is just that - a conservative cannabis investment.

Our Conservative Cannabis Stock Portfolio Continues To Outperform

Tilray Medical launches Redecan cannabis brand in Australia

Jefferies analyst Owen Bennett maintained a Buy rating on Tilray (TLRY – Research Report) today and set a price target of $2.50. The company's shar...

Jefferies Sticks to Its Buy Rating for Tilray (TLRY)

IMBBY

YMAB

Press Releases

Tilray Brands Completes Acquisition of Craft Beer Brands and Breweries from Molson Coors Beverage Company

Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms

Breckenridge Brewery Unveils Oktoberfest Brew and Hosts 28th Annual Oktoberfest Festival: A Weekend of Live Music, Traditional German Cuisine, and Tasty Brews in Breckenridge, Colorado

Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company

Tilray Medical Launches Redecan Cannabis Brand in Australia

Sports

Shock Top Announces its Official Craft Beer Sponsorship of University of Missouri Athletics

Restaurants

Tilray Brands Leverages Hemp and Beverage Scale to Launch Hemp-Derived Delta-9 THC Drinks in Key Markets Across the United States

Shock Top's Bold New Hard Iced LiiT Tea is Here

Tilray Brands, Inc. to Announce First Quarter Fiscal Year 2025 Financial Results on October 10, 2024

Comments

Tilray Brands

매도 수량

Tilray Brands (NASDAQ:TLRY) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌